These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2273081)

  • 1. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients.
    Kirch W; Hutt HJ; Plänitz V
    J Clin Pharmacol; 1990 Dec; 30(12):1088-95. PubMed ID: 2273081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General pharmacology of the novel centrally acting antihypertensive agent moxonidine.
    Armah BI; Hofferber E; Stenzel W
    Arzneimittelforschung; 1988 Oct; 38(10):1426-34. PubMed ID: 3196383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives.
    Wenzel RR; Spieker L; Qui S; Shaw S; Lüscher TF; Noll G
    Hypertension; 1998 Dec; 32(6):1022-7. PubMed ID: 9856967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension.
    Mitrovic V; Patyna W; Hüting J; Schlepper M
    Cardiovasc Drugs Ther; 1991 Dec; 5(6):967-72. PubMed ID: 1686975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why imidazoline receptor modulator in the treatment of hypertension?
    Schäfer SG; Kaan EC; Christen MO; Löw-Kröger A; Mest HJ; Molderings GJ
    Ann N Y Acad Sci; 1995 Jul; 763():659-72. PubMed ID: 7677385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Dickstein K; Manhenke C; Aarsland T; Køpp U; McNay J; Wiltse C
    Am J Cardiol; 1999 Jun; 83(12):1638-44. PubMed ID: 10392868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla.
    Haxhiu MA; Dreshaj I; Schäfer SG; Ernsberger P
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S1-8. PubMed ID: 7533221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
    Prichard BN; Graham BR
    Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of moxonidine in the treatment of hypertension.
    Prichard BN; Graham BR
    J Hypertens Suppl; 1997 Jan; 15(1):S47-55. PubMed ID: 9050986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: moxonidine versus captopril.
    Kraft K; Vetter H
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S29-33. PubMed ID: 7533224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers.
    Trenk D; Wagner F; Jähnchen E; Plänitz V
    J Clin Pharmacol; 1987 Dec; 27(12):988-93. PubMed ID: 3437071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in blood pressure, plasma catecholamines and plasma renin activity during and after treatment with tiamenidine and clonidine.
    Hansson BG; Hökfelt B
    Br J Clin Pharmacol; 1981 Jan; 11(1):73-7. PubMed ID: 7011348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moxonidine: a new and versatile antihypertensive.
    Messerli F
    J Cardiovasc Pharmacol; 2000; 35(7 Suppl 4):S53-6. PubMed ID: 11346219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraindividual comparison of moxonidine and prazosin in hypertensive patients.
    Plänitz V
    Eur J Clin Pharmacol; 1986; 29(6):645-50. PubMed ID: 3709608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of moxonidine, an I1-imidazoline receptor agonist.
    Ziegler D; Haxhiu MA; Kaan EC; Papp JG; Ernsberger P
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S26-37. PubMed ID: 8872297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension.
    Küppers HE; Jäger BA; Luszick JH; Gräve MA; Hughes PR; Kaan EC
    J Hypertens; 1997 Jan; 15(1):93-7. PubMed ID: 9050976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.